Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells'. The fol... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safe... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevac... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Vers... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy ... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharmaco... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembro... Read More